Specialized Programs of Research Excellence (SPOREs) in Human Cancers
National Institutes of Health (NIH)
Maximum of $1,400,000 in direct costs per year for up to 5 years.
To support state-of-the-art investigator-initiated translational research that contributes to improved prevention, early detection, diagnosis, and treatment of organ-specific cancers.
Researchers in cancer biology and treatment.
Patients with organ-specific cancers.
Underserved populations affected by cancer health disparities.
Eligible organization types include higher education institutions, nonprofits, for-profit organizations, small businesses, local, state, and federal governments, and Indian/Native American tribal governments.
Non-domestic (non-U.S.) entities are not eligible to apply.
U.S. organizations are eligible; non-domestic components of U.S. organizations are not eligible.
Projects must focus on organ-specific cancers or groups of related cancers.
At least one project must propose a clinical trial.
Projects must include a laboratory component and a human endpoint.
Maximum of $1,400,000 in direct costs per year.
Additional funding of up to $120,000 per year for projects focusing on early detection, prevention, or population science.
Application deadlines are set for January 25, May 25, and September 25 of each year from 2024 to 2026.
All applications are due by 5:00 PM local time of the applicant organization.
Investigators may only serve as a PI/multi-PI on one funded SPORE P50 at a time.
Applications must follow the Multi-Project Instructions in the How to Apply - Application Guide.
Applications will be evaluated based on significance, innovation, approach, and the qualifications of the investigators.
Applications will undergo peer review and will be evaluated for scientific and technical merit.
Priority will be given to projects that address significant barriers in cancer research and demonstrate potential for high impact.
Projects must include a clinical trial component.
Non-domestic entities are not eligible, which may limit collaboration opportunities.
Encouragement of projects focusing on cancer health disparities.
Strong emphasis on translational research may provide a competitive edge for applicants with relevant experience.
Demonstrating a strong research base and collaboration among institutions.
Failure to include a clinical trial component.
Engage with NCI staff early in the application process.
Highlight unique aspects of the proposed research and its potential impact on cancer treatment.